BSECompany Update3d ago · 16 Aug 2026, 08:02 pm
Intimation of Investors meeting organised by Nuvama Wealth Management Limited and ICICI Securities Limited
Natco Pharma Ltd · 524816
✦ AI SummaryMgmt Change
Natco Pharma Ltd has announced an investor meeting organized by Nuvama Wealth Management Limited and ICICI Securities Limited on August 19th and 21st, 2026, in Mumbai. The meeting is not intended to discuss unpublished price sensitive information.
Analysis Scores
Earnings Impact1/10
Growth Catalyst1/10
Governance Concern1/10
Regulatory Risk1/10
Balance Sheet Risk1/10
Liquidity Impact8/10
Market Sentiment5/10
✦ Ask a Question
Ask anything about this announcement — AI will answer based on the filing content.
Full Announcement
Natco Pharma Ltd - 524816 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
Attachments (1)
📄pdf
Download →
8cb9add5-2dd7-4e4a-88f2-1c48230740c2.pdf
View document text
16th August 2026
Corporate Relationship Department The Manager - Listing
M/s. BSE Limited M/s. National Stock Exchange of India Ltd
Mumbai 400001 Bandra (E) Mumbai 400051
Scrip Code: 524816 Scrip Code: NATCOPHARM
Dear Sir/Madam,
Sub: Intimation of Schedule of investors meet
Ref: Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and
Disclosure Requirements) Regulations, 2015
Pursuant to Regulation 30(6) read with Para A of Part A of Schedule III of the Listing
Regulations, this is to inform you that the officials of the company will be participating in the
following investor meeting:
Date of Time Investor / Meeting Type of Nature of Location
meeting name meeting Meeting
Wednesday, 9:00 AM to Investors meeting In-person Group Mumbai,
19th August 5:00 PM organised by meeting Maharashtra
2026 to Nuvama Wealth
Friday, 21st Management
August Limited and ICICI
2026 Securities Limited
The schedule of the above-mentioned meeting is subject to change, and the change may occur
due to exigencies on the part of Investor / Company.
No Unpublished Price Sensitive Information (UPSI) pertaining to the Company is intended to
be discussed during the interactions.
Kindly take the same on record.
Thanking you,
Yours faithfully,
For NATCO Pharma Limited
Ch. Venkat Ramesh
Company Secretary &
Compliance Officer